Vascular Disrupting Agent Arsenic Trioxide Enhances Thermoradiotherapy of Solid Tumors
Author(s) -
Robert J. Griffin,
Brent Williams,
Nathan A. Koonce,
John C. Bischof,
Chang W. Song,
Rajalakshmi Asur,
Meenakshi Upreti
Publication year - 2012
Publication title -
journal of oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.228
H-Index - 54
eISSN - 1687-8469
pISSN - 1687-8450
DOI - 10.1155/2012/934918
Subject(s) - arsenic trioxide , medicine , hyperthermia , cisplatin , radiation therapy , cancer research , in vivo , apoptosis , trioxide , necrosis , chemotherapy , pathology , chemistry , biology , biochemistry , sulfur , microbiology and biotechnology , organic chemistry
Our previous studies demonstrated arsenic trioxide- (ATO-) induced selective tumor vascular disruption and augmentation of thermal or radiotherapy effect against solid tumors. These results suggested that a trimodality approach of radiation, ATO, and local hyperthermia may have potent therapeutic efficacy against solid tumors. Here, we report the antitumor effect of hypofractionated radiation followed by ATO administration and local 42.5 °C hyperthermia and the effects of cisplatin and thermoradiotherapy. We found that the therapeutic efficacy of ATO-based thermoradiotherapy was equal or greater than that of cisplatin-based thermoradiotherapy, and marked evidence of in vivo apoptosis and tumor necrosis were observed in ATO-treated tumors. We conclude that ATO-based thermoradiotherapy is a powerful means to control tumor growth by using vascular disruption to augment the effects of thermal and radiation therapy.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom